12月31日，安杰思跌1.08%，截至发稿，报58.59元/股，成交2297.36万元，换手率0.94%，总市值47.53 亿元。 资料显示，杭州安杰思医学科技股份有限公司位于浙江省杭州市临平区兴中路389号，成立日期2010年 12月6日，上市日期2023年5月19日，公司主营业务涉及从事内镜微创诊疗器械的研发、生产与销售。主 营业务收入构成为：GI类62.74%，EMR/ESD类23.26%，ERCP类11.04%，仪器类2.21%，其他0.74%。 从基金十大重仓股角度 数据显示，华泰保兴基金旗下1只基金重仓安杰思。华泰保兴健康消费A（006882）三季度持有股数 3640股，占基金净值比例为6.03%，位居第六大重仓股。根据测算，今日浮亏损失约2329.6元。 华泰保兴健康消费A（006882）成立日期2019年5月27日，最新规模74.14万。今年以来亏损14.34%，同 类排名8076/8085；近一年亏损15.05%，同类排名8073/8085；成立以来亏损10.2%。 华泰保兴健康消费A（006882）基金经理为赵旭照。 截至发稿，赵旭照累计任职时间7年353天，现任基金资产总规模6.53亿元 ...

证券之星消息，根据天眼查APP-财产线索数据整理，根据内蒙古自治区国际蒙医医院12月28日发布的 《内蒙古自治区国际蒙医医院二期扩建工程彩超、吊塔等医疗设备采购项目政府采购合同公告》内容显 示，山东新华医疗器械股份有限公司中标，详情如下： 标题：内蒙古自治区国际蒙医医院二期扩建工程彩超、吊塔等医疗设备采购项目政府采购合同公告 通过天眼查大数据分析，山东新华医疗器械股份有限公司共对外投资了53家企业，参与招投标项目 11487次；财产线索方面有商标信息211条，专利信息4558条，著作权信息380条；此外企业还拥有行政 许可346个。 采购方：内蒙古自治区国际蒙医医院 供应商：山东新华医疗器械股份有限公司 中标金额：1159000.0 地区：内蒙古自治区 发布日期：2025-12-28 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 数据来源：天眼查APP ...

Core Viewpoint - The National Medical Products Administration (NMPA) of China has released the "Priority Approval Catalog for High-end Medical Devices (2025 Edition)", which includes eight advanced medical devices for expedited approval, aiming to accelerate the market entry of innovative high-end medical equipment [1]. Group 1: Priority Approval Catalog - The catalog includes advanced medical devices such as the boron neutron capture therapy system, ultra-high field magnetic resonance imaging equipment, medical electron accelerators, and implantable brain-machine interface devices [1][2]. - The NMPA will implement priority approval for the medical devices listed in the catalog according to Article 73, Item 3 of the "Regulations on the Registration and Filing of Medical Devices" [1][5]. Group 2: Device Specifications - The boron neutron capture therapy system is designed to treat malignant tumors that are recurrent or for which there are no other conventional treatment options, utilizing a reaction between neutrons and boron to produce secondary particles that kill cancer cells [2]. - The ultra-high field magnetic resonance imaging equipment has a magnetic field strength greater than 5 Tesla [2]. - The medical electron accelerator integrates magnetic resonance imaging guidance and is used for various therapeutic applications [2]. - The implantable brain-machine interface device captures neural signals from the central nervous system through implanted electrodes, enabling interaction with external control devices for compensating motor and sensory dysfunctions [2]. - The endoscopic surgical control system employs robotic technology for operating surgical instruments through natural orifices [2]. - The transcatheter tricuspid valve repair system is suitable for high-risk patients with severe tricuspid regurgitation who are deemed unsuitable for surgical intervention [2]. - The minimally invasive glaucoma surgery (MIGS) implant establishes a drainage pathway for aqueous humor in the eye [2].

Core Viewpoint - Micron Heart Technology-B (02160.HK) has reported significant growth in the adoption of its VitaFow® series transcatheter aortic valves and delivery systems (TAVI), with a projected increase in implant volume for 2025 [1] Group 1: Product Performance - The VitaFow® series TAVI has been introduced in 35 countries and regions globally, with a cumulative implant volume nearing 1,300 cases [1] - The implant volume for 2025 is expected to exceed 850 cases, representing a nearly 350% increase compared to 2024 [1] - In the second half of 2025, the implant volume is anticipated to grow by over 170% compared to the first half, driven by the commercialization of VitaFow Liberty® following CE certification in European countries [1] Group 2: Market Expansion - The company is focusing on expanding its market share in emerging markets in Asia and Latin America, contributing to the anticipated growth in implant volumes [1]

Core Viewpoint - Anbiping's stock price has shown significant fluctuations, with a year-to-date increase of 41.20%, but a recent decline over the past 60 days, indicating potential volatility in the market [1][2]. Group 1: Stock Performance - As of December 31, Anbiping's stock price reached 24.30 CNY per share, with a trading volume of 19.08 million CNY and a turnover rate of 0.86%, resulting in a total market capitalization of 2.274 billion CNY [1]. - The stock has experienced a net outflow of 2.6093 million CNY from major funds, with large orders accounting for 1.22% of total purchases and 14.89% of total sales [1]. - Over the past five trading days, the stock has increased by 4.47%, while it has decreased by 8.92% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Anbiping reported a revenue of 253 million CNY, reflecting a year-on-year decrease of 28.29%, and a net profit attributable to shareholders of -10.77 million CNY, a decline of 136.34% [2]. - The company has distributed a total of 87.7965 million CNY in dividends since its A-share listing, with 36.4595 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, Anbiping had 7,567 shareholders, a decrease of 17.94% from the previous period, while the average number of circulating shares per person increased by 21.86% to 12,365 shares [2]. - Among the top ten circulating shareholders, Changcheng Consumption Value Mixed A holds 850,000 shares, with no change in the number of shares held compared to the previous period [3].

Group 1 - Core viewpoint: Berry Genomics has seen a stock price increase of 1.25%, reaching 11.30 CNY per share, with a total market capitalization of 3.995 billion CNY as of the report date [1] - Company overview: Berry Genomics, established on April 14, 1997, specializes in gene testing and sales of related equipment and reagents, with its main revenue sources being reagent sales (45.74%), medical testing services (31.24%), basic research services (18.33%), equipment sales (3.48%), and others (1.20%) [1] Group 2 - Major shareholders: The top circulating shareholder of Berry Genomics includes a fund from Yongying Fund, with the Medical Device ETF (159883) newly entering the top ten shareholders in Q3, holding 1.5268 million shares, which is 0.46% of the circulating shares [2] - ETF performance: The Medical Device ETF (159883) has a total size of 4.73 billion CNY, with a year-to-date return of 1.32%, ranking 3982 out of 4189 in its category, and a one-year loss of 0.34%, ranking 4000 out of 4188 [2]

据悉，全球首创的核心产品K-Clip®经导管三尖瓣介入修复系统，复刻经典外科手术，通过微创手术修 复三尖瓣反流，已于2025年3月获得国家药品监督管理局（NMPA）批准上市，目前已经开展了大规模 商业化应用。 来源：猎云网 汇禾医疗董事长林林表示："汇禾医疗将继续在心血管介入领域不断突破创新，为患者带来更微创、更 安全的治疗方案，为医生提供更简便、更可控的手术工具，为全球医疗健康事业贡献中国智慧和中国方 案。" 这是汇禾医疗继2022年完成C+轮融资以来的又一重要里程碑，标志着公司在结构性心脏病介入治疗领 域的创新实力获得资本市场高度认可。 天眼查显示，汇禾医疗是一家具有自主创新能力的世界领先的心血管介入平台公司，专注于心血管介入 医疗器械的研发、生产和商业化，公司在结构性心脏病、血管介入及智能介入等领域，均有自主研发世 界领先的产品。 近日，上海汇禾医疗科技股份有限公司（以下简称"汇禾医疗"）宣布完成D轮融资，本轮融资由太平医 疗健康基金战略领投，老股东苏州夏尔巴二期股权投资合伙企业（有限合伙）跟投（以下简称"夏尔 巴"）。 ...

明德生物（002932）公告称，公司拟以现金方式收购武汉必凯尔救助用品有限公司100%股权，预计本 次交易构成重大资产重组。 与此同时，A股新能源赛道也有大消息。12月30日晚间，盐湖提锂龙头盐湖股份（000792）发布关于公 司拟以46.05亿元现金收购控股股东中国盐湖工业集团持有的五矿盐湖有限公司51%股权的公告。本次 交易完成后，五矿盐湖将成为公司的控股子公司，并纳入公司合并报表范围。 12月30日晚间，多家A股上市公司发布重要公告，披露了关于并购重组的最新进展。 公告显示，五矿盐湖的主要产品为碳酸锂、磷酸锂、氢氧化锂和氯化钾，目前已建成碳酸锂产能1.5万 吨/年、磷酸锂产能0.2万吨/年、氢氧化锂产能0.1万吨/年以及钾肥产能30万吨/年。 中能电气（300062）公告称，公司决定终止筹划收购山东达驰电气有限公司等65%股权及转让方对标的 企业享有的债权的重大资产重组事项。 盐湖股份表示，本次交易是为加快推进世界级盐湖产业基地建设，推动盐湖产业整合融合，妥善解决同 业竞争问题，持续提升上市公司质量。 东杰智能（300486）公告称，公司决定终止筹划收购遨博（北京）智能科技股份有限公司控股权的重大 资产 ...

Group 1 - On December 30, Aidi Te's stock rose by 3.21%, with a trading volume of 92.05 million yuan [1] - The financing data for Aidi Te on the same day showed a financing purchase amount of 12.65 million yuan and a financing repayment of 13.45 million yuan, resulting in a net financing buy of -0.80 million yuan [1] - As of December 30, the total balance of margin trading for Aidi Te was 112 million yuan, accounting for 3.47% of its circulating market value, which is above the 60th percentile level over the past year [1] Group 2 - As of September 30, Aidi Te had 9,851 shareholders, an increase of 4.66% from the previous period, while the average circulating shares per person decreased by 4.46% to 7,310 shares [2] - For the period from January to September 2025, Aidi Te achieved an operating income of 747 million yuan, representing a year-on-year growth of 16.44%, and a net profit attributable to the parent company of 142 million yuan, up 27.40% year-on-year [2] Group 3 - Aidi Te has distributed a total of 49.48 million yuan in dividends since its A-share listing [3]

Company Overview - Jingfeng Medical, established in 2017, focuses on the research and development of surgical robots, aiming to design, develop, and manufacture surgical robots. The company currently has three products at different stages of development, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots [8][21]. Product Pipeline - The product lineup includes two core products: Jingfeng's multi-port laparoscopic surgical robot and single-port laparoscopic surgical robot. The company has developed a comprehensive technology platform with seven core proprietary technology modules [8][24]. - The MP1000 is the first laparoscopic surgical robot approved for multiple surgical specialties, while the SP1000 is the first single-port laparoscopic surgical robot approved by the National Medical Products Administration (NMPA) for gynecological surgeries [21][22]. Market Size - The global surgical robot market is projected to grow significantly, with a compound annual growth rate (CAGR) of 18.9% from 2019 to 2024, 12.0% from 2024 to 2030, and 22.4% from 2030 to 2033. The market size is expected to reach approximately $84.19 billion by 2033 [15][19]. Industry Position - Jingfeng Medical has achieved significant milestones, including obtaining NMPA approval for the MP1000 in December 2022 and expanding its application range to gynecology, general surgery, and thoracic surgery by August 2023. The company has also received approval for the upgraded MP1000 Plus model in October 2023 [21][22]. - As of the latest available data, over 12,000 robotic-assisted clinical surgeries in China have been performed using the company's multi-port laparoscopic surgical robot, and over 2,000 surgeries using the single-port laparoscopic surgical robot [23][24]. Financial Data - The total revenue for the company is projected to be 1.60 billion RMB in 2023, with forecasts of 1.49 billion RMB in 2024 and 0.48 billion RMB by June 30, 2025. The financial figures indicate a growing trend in revenue generation [37][38].